A Study of mRNA-1608, a Herpes Simplex Virus -2 (HSV-2) Therapeutic Candidate Vaccine, in Healthy Adults 18 to 55 Years of Age With Recurrent HSV-2 Genital Herpes
Completed · Phase 1, Phase 2 · NCT06033261
Conditions: Genital Herpes
At a glance
- Research payments reported, 2025
- $2.4M
- U.S. investigators named
- 22
- Sites paid
- 18
- Planned or actual enrollment
- 303
About the trial
- Sponsor
- ModernaTX, Inc.
- Tested
- mRNA-1608 (biological), BEXSERO (biological)
- Dates
- Started 2023-09-06; completion 2025-04-25
- Results posted
- Yes
The purpose of this study is to generate safety and immunogenicity data and establish a proof-of-concept of clinical benefit of the mRNA-1608 vaccine candidate.
From ClinicalTrials.gov, last updated 2026-05-08. Full record, eligibility and contacts (opens in a new tab)
Industry funding
ModernaTX, Inc. reported $2.4M in research payments for this study in 2025 (1,191 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Rowell S. Ashford II, M.D. OB-GYN (Obstetrics & Gynecology) · Ensley, AL
- Dena E. Petersen, MD Family Medicine · Tucson, AZ
- Aaron S. Weinberg, M.D. Pulmonology · Irvine, CA
- Lisa M. Cohen, D. O. Family Medicine · Palm Harbor, FL
- Luis P. Leyva JR., M.D. OB-GYN (Obstetrics & Gynecology) · Miami, FL
- Guy S. Strauss, D.O. Internal Medicine · Lake City, FL
- Martha S. Fanning, M.D. Emergency Medicine · Overland Park, KS
- Carlos A. Fierro, MD General Practice · Kansas City, KS
- Robyn D. Hartvickson, MD Family Medicine · Newton, KS
- Corey Hebert Pediatrics · Gretna, LA
- Rebecca A. Rivard, D.O. Family Medicine · Roseville, MI
- Adam B. Brosz, M.D. Family Medicine · Grand Island, NE
- Keith W. Vrbicky, M.D. OB-GYN (Obstetrics & Gynecology) · Norfolk, NE
- Matthew G. Davis, MD Family Medicine · Rochester, NY
- Margaret E. Rhee, MD OB-GYN (Obstetrics & Gynecology) · Akron, OH
- Kenneth H. Mayer, M.D. Infectious Disease · Providence, RI
- Gregg H. Lucksinger, M.D. Family Medicine · Austin, TX
- Vicki E. Miller, M.D. Family Medicine · Pasadena, TX
- Cynthia J. Robbins, M.D. OB-GYN (Obstetrics & Gynecology) · Fort Worth, TX
- Sheila E. Schmidt, M.D. General Practice · Pearland, TX
- George H. Freeman, M.D. Research Study Specialist · Newport News, VA
- Christine M. Johnston Infectious Disease · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Velocity Clinical Research Inc $448,577
- Research Works Inc $222,442
- University of Washington Medical Ctr, WA $220,818
- Texas Center for Drug Development Inc $181,339
- Helios Cr Inc $169,504
- Carbon Health Technologies Inc $159,099
- Dynamed Clinical Research LP $149,187
- Suncoast Research Associates LLC DBA Sra Trials $143,620
- Noble Clinical Research LLC $141,813
- Health Research of Hampton Roads Inc $112,810
- Johnson County Clintrials LLC $107,975
- Dynamed Detroit LLC $87,987
- Rochester Clinical Research LLC $78,658
- Fenway Community Health Center Inc $74,422
- Wr Msra LLC $58,283
- M3 Wake Research Inc $23,323
- Alliance for Multispecialty Research LLC $17,732
- Achieve Clinical Research LLC $17
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.